Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Esperion Therapeutics $250 million convertible senior subordinated notes
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Esperion…
Maravai LifeSciences Holdings $1.863 billion IPO
Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 69…
Stoke Therapeutics $112 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $112 million public offering of 2,500,000…
Berkeley Lights $258 million secondary offering
Davis Polk advised the representatives of the several underwriters in connection with the $258 million SEC-registered…
Olema Pharmaceuticals $240 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public…
Signify Health acquisition of PatientBlox
Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective…
Antengene HK$2.79 billion IPO
Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong…
Auna $300 million high-yield notes offering
Davis Polk advised Auna S.A.A. in connection with its Rule 144A/Regulation S offering of $300 million aggregate principal…
Kodiak Sciences $645 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $645…
China Biologic going-private transaction
Davis Polk is advising the special committee of the board of directors of China Biologic Products Holdings, Inc. (“China…